Back to Search
Start Over
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
- Source :
-
Expert opinion on drug safety [Expert Opin Drug Saf] 2017 Sep; Vol. 16 (9), pp. 1009-1019. Date of Electronic Publication: 2017 Jul 12. - Publication Year :
- 2017
-
Abstract
- Introduction: The prevalence of Alzheimer's disease (AD) continues to rise, while treatment options for cognitive impairment are limited. Acetylcholinesterase inhibitors (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these drugs are not without adverse events (AEs). The safety profile of each drug must be taken carefully into consideration before being prescribed, as new dosages and formulations have recently been approved. Areas covered: Donepezil, galantamine and rivastigmine are the three AChEIs approved for the treatment of varying stages of AD. Numerous clinical trials and post-marketing studies have evaluated the safety of these medications. This article will review the safety, efficacy and tolerability of these drugs in treating AD. Topics including pharmacovigilance databases, concomitant drug interactions, prescribing cascades, and treatment discontinuation are also covered. Expert opinion: AChEI use in those with mild, moderate or severe AD provide modest improvements in cognition, function and behavior. The pharmacological treatment of AD using AChEIs is associated with generally mild AEs. Differences in drug formulations should be taken into account when determining the most appropriate route of administration for each individual. Furthermore, discontinuation of AChEIs must be carefully monitored as it may be associated with worsening cognitive impairment.
- Subjects :
- Alzheimer Disease physiopathology
Cholinesterase Inhibitors adverse effects
Cognition Disorders drug therapy
Cognition Disorders physiopathology
Dementia physiopathology
Donepezil
Drug Interactions
Galantamine adverse effects
Galantamine therapeutic use
Humans
Indans adverse effects
Indans therapeutic use
Piperidines adverse effects
Piperidines therapeutic use
Rivastigmine adverse effects
Rivastigmine therapeutic use
Severity of Illness Index
Alzheimer Disease drug therapy
Cholinesterase Inhibitors therapeutic use
Dementia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-764X
- Volume :
- 16
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Expert opinion on drug safety
- Publication Type :
- Academic Journal
- Accession number :
- 28678552
- Full Text :
- https://doi.org/10.1080/14740338.2017.1351540